Business
-
Clinical Trials
Phase I-III Clinical Trials、Real-world Study、Food-effect、DDI -
Regulatory Affairs
Review and Writing of Pharmaceutical R&D Site Documents、Product Site Audit and Inspection、R&D QMS -
Medical Affairs
Clinical Trials Protocol design and writing、PV、Medical Monitoring -
Quality Management
Review and Writing of Pharmaceutical R&D Site Documents、Product Site Audit and Inspection、R&D QMS -
Mass Balance
Provide One-stop Special Services with Value -
Quantitative Pharmacology Analysis
Drug interation and pharmacokinetics in special populations, optimization of initial dose and effective dose -
Biological Detection
preclinical and clinical, radioactive and non-radioactive DMPK studies -
Data Management and Statistical Analysis
Data Management、Biostatistical Analysis Meta Analysis
News
-
2024-09-12
LIVE BROADCAST | Drug-drug Interaction Evaluation Strategies: From In Vitro to Clinical Studies
Yeedozencom will hold an online broadcast titled “Yeedo Share” on September 12, at 19:00. Dr. Yu Feifei, Deputy Director of the Medical Department at Yeedozencom, will present on the topic of “Drug-drug Interaction Evaluation Strategies: From In Vitro to Clinical Studies”.Learn more -
2024-09-12
GOOD NEWS | Congratulations to Homesun Pharmaceutical on the Marketing Approval of Levofloxacin Tablets, Amiodarone Hydrochloride Injection, and Acetylcysteine Solution for Inhalation
Recently, Suzhou Homesun Pharmaceutical Co., Ltd. (hereinafter referred to as “Homesun Pharmaceutical”), received approval letters from the National Medical Products Administration (NMPA) for their products Levofloxacin Tablets (0.5 g), Amiodarone Hydrochloride Injection (3 mL:150 mg), and Acetylcysteine Solution for Inhalation (3 mL:0.3 g).Learn more -
2024-09-12
GOOD NEWS | Congratulations to GenFleet Therapeutics on the marketing approval of their innovative drug, Fulzerasib
On August 21, 2024, Dupert® (Fulzerasib tablets) developed by GenFleet Therapeutics was approved by the National Medical Products Administration (NMPA) for marketing as a treatment of advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) in patients who have received at least one prior line of systemic therapy, marking it as the first approved KRAS G12C inhibitor in China.Learn more